ArticleClinical and experimental dental research2024
Comparison of Salivary Opiorphin in Burning Mouth Syndrome and Healthy Subjects and Its Correlation With Psychiatric Disorders.
Article in Clinical and experimental dental research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exploration of a pain assessment tool on burning mouth syndrome.Journal of oral & facial pain and headache · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectivesBurning mouth syndrome (BMS) is a chronic disease in which the patient experiences a burning sensation in the oral mucosa without any pathological cause. Opiorphin is a pentapeptide that prevents pain and can have an antidepressant effect. The aim of this study was to evaluate salivary opiorphin concentration in BMS and healthy subjects. In addition, opiorphin concentration in BMS patients before and after psychiatric treatment was compared and the association between burning severity and psychiatric scores with salivary opiorphin concentration was examined. MATERIALS AND
methodsThis cross-sectional study included 28 BMS patients and 40 healthy individuals referred to the Department of Oral and Maxillofacial Medicine, Faculty of Dentistry, Mashhad, from September 2018 to August 2019. Patients with proven disease based on clinical and psychiatric examinations were included in the study. Unstimulated salivary opiorphin levels were assessed by ELISA. Statistical analysis was performed using SPSS version 24.
resultsSalivary opiorphin levels were significantly higher in BMS patients (2.16 ± 0.30 ng/mL) than in healthy subjects (1.80 ± 0.36 ng/mL) (p < 0.001). Opiorphin levels in BMS patients increased insignificantly after psychiatric therapy (p = 0.212). In addition, there was no significant association between opiorphin levels and age, gender, menopause, burning severity, anxiety, and depression status.
conclusionsThe opiorphin concentration in saliva is higher in BMS patients than in healthy subjects. Most BMS patients also suffer from anxiety and depression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.